TP53 and ovarian cancer: We report on the performance of longitudinal multi-marker algorithms incorporating CA125, HE4, CA72-4 and anti-TP53 autoantibodies as a first-line test in ovarian cancer screening using the prospective specimen collection and the retrospective blinded evaluation (PRoBe) design [23] within the general population UKCTOCS trial.